Core Insights - Cidara Therapeutics, Inc. will report its Q3 2025 financial results and operational highlights on November 6, 2025, after U.S. market close [1] - A conference call and webcast will be held at 5:00 PM Eastern Time to discuss the results and business updates [2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies [3] - The lead DFC candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [3] - CD388 received Fast Track Designation from the FDA in June 2023 and has shown positive results in the Phase 2b NAVIGATE trial in June 2025, with a Phase 3 ANCHOR trial initiated in September 2025 [3]

Table of Contents As filed with the Securities and Exchange Commission on July 19, 2024 REGISTRATION NO. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CIDARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1537286 (State or other jurisdiction of incorporation or organization) 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 (858) 752-6170 (Address, including zip ...